LON:AVO

Advanced Oncotherapy Share Forecast, Price & News

GBX 34
+1.38 (+4.23 %)
(As of 07/28/2021 12:00 AM ET)
Add
Compare
Today's Range
32.98
35
50-Day Range
31
38.75
52-Week Range
24.46
50
Volume66,444 shs
Average Volume151,501 shs
Market Capitalization£118.94 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AVO News and Ratings via Email

Sign-up to receive the latest news and ratings for Advanced Oncotherapy and its competitors with MarketBeat's FREE daily newsletter.


Advanced Oncotherapy logo

About Advanced Oncotherapy

Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, selling, and maintaining proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.73 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Advanced Oncotherapy (LON:AVO) Frequently Asked Questions

What stocks does MarketBeat like better than Advanced Oncotherapy?

Wall Street analysts have given Advanced Oncotherapy a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Advanced Oncotherapy wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Advanced Oncotherapy's next earnings date?

Advanced Oncotherapy is scheduled to release its next quarterly earnings announcement on Monday, September 27th 2021.
View our earnings forecast for Advanced Oncotherapy
.

How were Advanced Oncotherapy's earnings last quarter?

Advanced Oncotherapy plc (LON:AVO) announced its earnings results on Monday, June, 29th. The company reported ($9.83) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($8.90) by $0.93.
View Advanced Oncotherapy's earnings history
.

How has Advanced Oncotherapy's stock price been impacted by COVID-19 (Coronavirus)?

Advanced Oncotherapy's stock was trading at GBX 32.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AVO shares have increased by 4.6% and is now trading at GBX 34.
View which stocks have been most impacted by COVID-19
.

Who are Advanced Oncotherapy's key executives?

Advanced Oncotherapy's management team includes the following people:
  • Dr. Michael Jeffrey Sinclair, Exec. Chairman (Age 78, Pay $554.93k)
  • Mr. Nicolas Serandour, CEO & Exec. Director
  • Prof. Stephen Myers, Exec. Director (Age 74, Pay $255.69k)
  • Mr. Ed Lee, COO & Pres of Europe
  • Mr. Graham Pughe, Sr. Vice-Pres of Accounting
  • Dr. Manuel Gallas, Director of Technical & Engineering
  • Mr. David Navas, VP of Investor and PR
  • Ms. Bridget Biggar, Director of HR
  • Ms. Donatella Ungaro, Managing Director of ADAM
  • Ms. Marina Giunta, Head of Physics Group

Who are some of Advanced Oncotherapy's key competitors?

What other stocks do shareholders of Advanced Oncotherapy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Advanced Oncotherapy investors own include UK Oil & Gas (UKOG), Avesoro Resources (ASO), Oxford Biomedica (OXB), BMR Group (BMR), GW Pharmaceuticals (GWPH), Lancashire (LRE), Sirius Minerals (SXX), Renishaw (RSW), Scancell (SCLP) and Tullow Oil (TLW).

What is Advanced Oncotherapy's stock symbol?

Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO."

How do I buy shares of Advanced Oncotherapy?

Shares of AVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Advanced Oncotherapy's stock price today?

One share of AVO stock can currently be purchased for approximately GBX 34.

How much money does Advanced Oncotherapy make?

Advanced Oncotherapy has a market capitalization of £118.94 million.

How many employees does Advanced Oncotherapy have?

Advanced Oncotherapy employs 129 workers across the globe.

What is Advanced Oncotherapy's official website?

The official website for Advanced Oncotherapy is www.advancedoncotherapy.com.

Where are Advanced Oncotherapy's headquarters?

Advanced Oncotherapy is headquartered at Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom.

How can I contact Advanced Oncotherapy?

Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728.


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.